Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

A Better Family Plan

Staff  |  Issue: October 2007  |  October 1, 2007

So, how can we optimize the chances for pregnancy success for a woman with SLE? Are there strategies that we can use to decrease her risks? Can we improve her chances of delivering a full-term, healthy baby? Fortunately, I think that we can. Here are some of the steps that we, as rheumatologists, can take to help our patients grow healthy babies.

Step 1: Conceive when Lupus is Quiescent

To give a pregnancy the best chance for success, the woman should have quiet lupus at the time of conception. The importance of lupus activity at the time of conception has been known for years.10 The Hopkins Lupus Cohort offers a clear demonstration of the negative effects of SLE activity at conception. In this cohort of 265 pregnancies, 42% of women with SLE activity in the six months prior to conception suffered a pregnancy loss, compared with 11% who conceived during a period of quiescence.11 Similarly, lupus activity in the first trimester – whether assessed with a physician’s global assessment, thrombocytopenia, or proteinuria – led to a several-fold increase in pregnancy loss over more stable SLE patients.12

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Though the timing of any pregnancy can be challenging, it is clearly important in women with SLE. Women with active lupus should be offered contraception in order to avoid the pregnancy tragedies that may result. Because women on cyclophosphamide may still be fertile during therapy, a pregnancy test should be performed prior to each intravenous dosage and contraception should be encouraged. Good contraception options for women with active lupus include progesterone-only pills or the Depo-provera shot, an intrauterine device (IUD), or barrier methods (condoms or a diaphragm). Though estrogen-containing oral contraceptives may be safe for women with mild or inactive lupus, they have not been tested in women with significant disease activity.13,14

It is important to weigh the potential risks of each medication to the developing fetus versus the benefit of each in maintaining low lupus activity prior to and during pregnancy.

Step 2: Continue Some Medications, Discontinue Others

The need to conceive when lupus is quiet brings us to the use of medications to control lupus activity. Discontinuing all medications when a woman is ready to conceive will often prompt an SLE flare, thus endangering her pregnancy. Therefore, it is important to weigh the potential risks of each medication to the developing fetus versus the benefit of each in maintaining low lupus activity prior to and during pregnancy. (See summary in Table 1.)

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 6 7 8 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Diagnostic CriteriaPathogenesispregnancySLEsystemic lupus erythematosus (SLE)systemic lupus erythematous

Related Articles

    Rheumatologists Should Discuss with Patients Use of Immunomodulatory Agents During Pregnancy

    November 16, 2016

    The decision to continue or discontinue immunomodulatory medications during pregnancy is a difficult one for both patients and physicians. On the one hand, when left untreated, rheumatic conditions can cause harm to an unborn child, as well as to the pregnant mother. On the other hand, medications can be harmful to a developing fetus. In…

    Challenges in Reproductive Health in Rheumatic Disease

    July 11, 2022

    In light of new challenges to individuals’ reproductive rights and the known challenges of clinical management of rheumatic disease patients during pregnancy, we review the current state of reproductive rheumatology and the management of patients with rheumatic disease during pregnancy.

    Treat to Target: Rheumatoid Arthritis in Pregnant Patients

    October 1, 2012

    A treat-to-target approach to managing rheumatoid arthritis can work even in pregnant women

    AndreyCherkasov / Shutterstock.com

    Rheumatic Disease Does Not Preclude Pregnancy

    November 9, 2017

    Preconception planning is essential to help women with autoimmune disease have optimal pregnancy outcomes. Unplanned pregnancy can also negatively impact disease course in some patients. Yet many rheumatologic patients of childbearing age do not receive adequate contraception or prepregnancy education and counseling. Rheumatologists must work collaboratively with other healthcare providers to make sure rheumatic patients…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences